Literature DB >> 28902071

Importance of Risk Perception: Predictors of PrEP Acceptance Among Thai MSM and TG Women at a Community-Based Health Service.

Rosalyn Plotzker1, Pich Seekaew, Jureeporn Jantarapakde, Supabhorn Pengnonyang, Deondara Trachunthong, Danai Linjongrat, Surang Janyam, Thitiyanun Nakpor, Sutinee Charoenying, Stephen Mills, Ravipa Vannakit, Michael Cassell, Praphan Phanuphak, Cheewanan Lertpiriyasuwat, Nittaya Phanuphak.   

Abstract

BACKGROUND: HIV prevalence among Thai men who have sex with men (MSM) and transgender women (TG) are 9.15% and 11.8%, respectively, compared with 1.1% in the general population. To better understand early adopters of pre-exposure prophylaxis (PrEP) in Thailand, we analyzed biobehavioral and sociodemographic characteristics of PrEP-eligible MSM and TG.
SETTING: Four Thai urban community clinics between October 2015 and February 2016.
METHODS: Sociodemographics, HIV risk characteristics, and PrEP knowledge and attitudes were analyzed in association with PrEP initiation among eligible Thai MSM and TG. Adjusted analysis explored factors associated with PrEP acceptance. We then analyzed HIV risk perception, which was strongly associated with PrEP initiation.
RESULTS: Of 297 participants, 55% accepted PrEP (48% of MSM, 54% of TG). Perceived HIV risk levels were associated with PrEP acceptance [odds ratio (OR): 4.3; 95% confidence interval (95% CI): 1.5 to 12.2. OR: 6.3; 95% CI: 2.1 to 19.0. OR: 14.7; 95% CI: 3.9 to 55.1; for minimal, moderate, and high perceived risks, respectively]. HIV risk perception was associated with previous HIV testing (OR: 2.2; 95% CI: 1.4 to 3.5); inconsistent condom use (OR: 1.8; 95% CI: 1.1 to 2.9); amphetamine use in the past 6 months (OR: 3.1; 95% CI: 1.1 to 8.6); and uncertainty in the sexually transmitted infection history (OR: 2.3; 95% CI: 1.4 to 3.7). Approximately half of those who reported either inconsistent condom use (46%), multiple partners (50%), group sex (48%), or had baseline bacterial sexually transmitted infection (48%) perceived themselves as having no or mild HIV risk.
CONCLUSIONS: HIV risk perception plays an important role in PrEP acceptance. Perception does not consistently reflect actual risk. It is therefore critical to assess a client's risk perception and provide education about HIV risk factors that will improve the accuracy of perceived HIV risk.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28902071     DOI: 10.1097/QAI.0000000000001536

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  20 in total

1.  Risk Behavior Not Associated with Self-Perception of PrEP Candidacy: Implications for Designing PrEP Services.

Authors:  Lu Xie; Yumeng Wu; Siyan Meng; Jianhua Hou; Rong Fu; Huang Zheng; Na He; Min Wang; Kathrine Meyers
Journal:  AIDS Behav       Date:  2019-10

2.  Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand.

Authors:  Natthapat Thongsak; Natthaporn Manojai; Rathawit Apiputhipan; Nicha Rongram; Natnita Mattawanon; Walaithip Bunyatisai; Bandhita Plubin; Nawapon Nakharutai; Salinee Thumronglaohapun; Pimwarat Srikummoon; Kanokkan Wongsawat; Patrinee Traisathit; Nontiya Homkham
Journal:  AIDS Behav       Date:  2022-08-05

3.  HIV Risk Factors and Risk Perception Among Adolescent Girls and Young Women: Results From a Population-Based Survey in Western Kenya, 2018.

Authors:  Vivienne Kamire; Faith Magut; Sammy Khagayi; Caroline Kambona; Hellen Muttai; Lucy Nganga; Daniel Kwaro; Rachael H Joseph
Journal:  J Acquir Immune Defic Syndr       Date:  2022-06-02       Impact factor: 3.771

4.  HIV Risk Perception and Pre-Exposure Prophylaxis (PrEP) Awareness Among Transgender Women from Mexico.

Authors:  Centli Guillen-Diaz-Barriga; Dulce Diaz-Sosa; Thiago S Torres; Kelika A Konda; Rebeca Robles-Garcia; Brenda Hoagland; Marcos Benedetti; Cristina Pimenta; Beatriz Grinsztejn; Carlos F Caceres; Valdilea G Veloso; Hamid Vega-Ramirez; Calzada México-Xochimilco
Journal:  AIDS Behav       Date:  2022-09-19

5.  Parallel reductions in anxiety and HIV-related worry among pre-exposure prophylaxis (PrEP) users over time.

Authors:  Devon M Price; Devin English; Sarit A Golub
Journal:  Health Psychol       Date:  2022-06       Impact factor: 5.556

Review 6.  Running with Scissors: a Systematic Review of Substance Use and the Pre-exposure Prophylaxis Care Continuum Among Sexual Minority Men.

Authors:  Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico
Journal:  Curr HIV/AIDS Rep       Date:  2022-06-14       Impact factor: 5.495

7.  HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy.

Authors:  Jillian Pintye; Kristin M Beima-Sofie; Pamela A Makabong'O; Anne Njoroge; Susan Brown Trinidad; Renee A Heffron; Jared M Baeten; Connie Celum; Daniel Matemo; John Kinuthia; Maureen C Kelley; Grace C John-Stewart
Journal:  AIDS Patient Care STDS       Date:  2018-07-23       Impact factor: 5.078

8.  Patterns and Correlates of Participant Retention in a Multi-City Pre-Exposure Prophylaxis Demonstration Project.

Authors:  Susanne Doblecki-Lewis; Albert Y Liu; Daniel J Feaster; Stephanie E Cohen; Richard Elion; Oliver Bacon; Megan Coleman; Gabriel Cardenas; Michael A Kolber
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

9.  PrEP eligibility, HIV risk perception, and willingness to use PrEP among high-risk men who have sex with men in India: A cross-sectional survey.

Authors:  Venkatesan Chakrapani; Peter A Newman; Murali Shunmugam; Shruta Rawat; Dicky Baruah; Ruban Nelson; Surachet Roungkraphon; Suchon Tepjan
Journal:  AIDS Care       Date:  2021-02-21

10.  Factors associated with awareness and use of pre-exposure prophylaxis (PrEP) among Black men who have sex with men with a recent STI diagnosis.

Authors:  Jessica L Maksut; Lisa A Eaton; Redd Driver; Cristina M Knowles; Ryan J Watson
Journal:  Behav Med       Date:  2020-06-17       Impact factor: 3.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.